Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma

European Journal of Surgical Oncology

Volumn 30, Issue 4, 2004, Pages 433-439

  Lindner P ^a   Thompson, J F ^a,b   de Wilt, J H W ^a   Colman, M ^a   Kam, P C A ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Isolated limb infusion; Isolated limb perfusion; Melanoma; Melphalan

Indexed keywords

ANTINEOPLASTIC AGENT; DACTINOMYCIN; MELPHALAN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; FEMALE; FREQUENCY ANALYSIS; HUMAN; LIMB DISEASE; MALE; MELANOMA; METASTASIS POTENTIAL; MORBIDITY; PRIORITY JOURNAL; TUMOR LOCALIZATION;

EID: 1942531976     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2004.01.015     Document Type: Article

References (23)

1. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997;132:903-907.
2. Kroon BBR, Fraker DL, Vrouenraets BC, Thompson JF. Isolated limb perfusion: results and complications. In: Thompson JF, Morton DL, Kroon BBR (eds) Textbook of melanoma. London: Martin Dunitz, 2004: 410-428.
3. Kroon BBR, Klaase JM, van Geel BN et al. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer 1993;29A:325-328.
4. DeVita VT. Principles of cancer management: chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Principles and practice of oncology. Philadelphia: Lippincott, 1997: 333-348.
5. Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Regional Cancer Treatment 1994;7:188-192.
6. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14: 238-247.
7. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-136.
8. Thompson JF, Kam PCA. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BBR (eds) Textbook of melanoma. London: Martin Dunitz, 2004: 429-437.
9. Thompson JF, Kam PCA, Saw RPM et al. Isolated limb infusion for melanoma: results of an elective double infusion protocol. Regional Cancer Treatment 1995;8:122-127.
10. Thompson JF, Eksborg S, Kam PC et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res 1996;6:267-271.
11. Thompson JF, Kam PCA, Lindner P. Isolated limb infusion. In: Balch CM, Houghton AN, Sober AJ, Soong S-J (eds) Cutaneous melanoma. St Louis: Quality Medical Publishing, 2003: 495-507.
12. Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994;4(Suppl. 1):45-50.
13. WHO handbook for reporting results of cancer treatments. WHO offset publication No. 48. Geneva: WHO, 1979.
14. Wieberdink J, Benckhuijsen C, Braat RP et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910.
15. Kaplan L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985;53:457-481.
16. Schraffordt Koops H, Vaglini M, Suciu S et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998;16:2906-2912.
17. Klaase JM, Kroon BBR, van Geel AN et al. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993;71:2990-2994.
18. Vrouenraets BC, Hart GA, Eggermont AM et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999;188:522-530.
19. Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996;83:1319-1328.
20. Klop WM, Vrouenraets BC, van Geel BN et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 1996;182:467-472.
21. Bartlett DL, Ma G, Alexander HR et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997;80: 2084-2090.
22. Feldman AL, Alexander HR Jr, Bartlett DL et al. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999;6:562-567.
23. McKay A, Byrne DS. Recurrent limb melanoma: treatments other than isolated limb perfusion and infusion. In: Thompson JF, Morton DL, Kroon BBR (eds) Textbook of melanoma. London: Martin Dunitz, 2004:443-448.